VGF expression by T lymphocytes in patients with Alzheimer's disease
| Autor: | Sabrina Greiner-Bohl, Johann Steiner, Bernhard Bogerts, Stefan Busse, Roland Hartig, Ursula Bommhardt, Henrik Dobrowolny, Christian Mawrin, Mandy Busse, Sarah Glorius |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Gerontology medicine.medical_specialty CD3 Complex T-Lymphocytes CD3 T cell T cells Rivastigmine Flow cytometry Research Paper: Gerotarget (Focus on Aging) Cerebrospinal fluid Alzheimer Disease Internal medicine medicine Humans Nerve Growth Factors Cells Cultured Aged Cell Proliferation Aged 80 and over Glycated Hemoglobin Sirolimus VGF expression medicine.diagnostic_test biology rapamycin Cell growth business.industry Alzheimer's disease Flow Cytometry medicine.disease Neuroprotective Agents Endocrinology Nerve growth factor medicine.anatomical_structure Oncology biology.protein Female Cytokine secretion business Biomarkers Immunosuppressive Agents |
| Zdroj: | Scopus-Elsevier Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.3569 |
| Popis: | Secretion of VGF is increased in cerebrospinal fluid and blood in neurodegenerative disorders like Alzheimer's disease (AD) and VGF is a potential biomarker for these disorders. We have shown that VGF is expressed in peripheral T cells and is correlated with T cell survival and cytokine secretion. The frequency of VGF+CD3+ T cells increases with normal aging. We found an increased number of VGF-expressing T cells in patients with AD compared to aged healthy controls, which was associated with enhanced HbA1c levels in blood. Upon treatment with rivastigmine, T cell proliferation and VGF expression in AD patients decreased to the level found in controls. Moreover, rapamycin treatment in vitro reduced the number of VGF+CD3+ cells in AD patients to control levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|